GSK, Impax drug works in Parkinson's study
London, August 17, 2011
An experimental Parkinson's disease drug from GlaxoSmithKline and Impax Laboratories has produced positive results in a second late-stage clinical trial.
The compound, IPX066, which is an extended release version of existing treatment carbidopa-levodopa (CD-LD), significantly improved symptoms in patients with advanced disease compared with standard CD-LD plus entacapone (CLE), the companies said.
The latest results follow success in an earlier phase III study announced in March, paving the way for the new medicine to be submitted for regulatory approval. Impax plans to file IPX066 with the U.S. Food and Drug Administration in the fourth quarter of 2011, while GSK will file it in Europe next year, it said.
GSK bought the rights to the drug from Impax in a deal worth up to $186.5 million last December.
In the latest phase III study, patients on the new drug reduced their "off time" - when the effects of anti-Parkinson's drugs wear off and symptoms return - to 24 percent, or 3.8 hours, during waking hours from 36.1 percent at the start of the trial. Those on CLE still had 32.5 percent "off time", or 5.2 hours.
Full results from the trial will be presented at an upcoming scientific meeting.
Shares in Impax jumped 11 percent in early Nasdaq trade, while GSK was up 1 percent, slightly outperforming a little changed European drugs sector. - Reuters
More Health & Environment Stories
- One more dead from SARS virus in Saudi
- Dubai Healthcare City inks deal with UAE universities
- University of Ain Shams opens MS treatment unit
- Bahrain's humidity could ease water crisis
- Visibility in Bahrain forecast to improve
- Bahrain-India venture plans hospitals in GCC
- Seha launches new health initiative
- Veolia backs Oman waste management meet
- Obesity rate at 72pc among Saudi adults
- Bahrain ideal for artificial rain experiment
- Riyadh 'among most polluted cities'
- CGM acquires 3 European healthcare IT providers
- The age of genomic medicine dawns, finally
- Over 300 exhibitors for Saudi healthcare event
- Mackeen unveils document management solution
- Seha opens new clinics in Abu Dhabi, Al Ain
- SARS virus claims one more victim in Saudi
- New support group comes to overeaters' rescue
- RAK Hospital launches urinary clinic for women
- NBAD backs Emiratis on Antarctica trip
- Cut sugar intake drastically urges WHO
- Al khaliji to fund Qatar recycling plant
- Qatar researcher in 360km breast cancer run
- New facilitator to open in DHCC
- Many countries lack capacity to prevent hearing loss
- QUIT NOW: Passive smoking hurts kids' arteries
- San Francisco to ban plastic water bottles
- GSK wins home toothpaste award for Sensodyne
- E-integration vital to GCC healthcare industry
- Fakih IVF unveils two new genetic tests